
Athira Pharma ATHA
Quarterly report 2025-Q3
added 11-06-2025
Athira Pharma Accounts Payables 2011-2026 | ATHA
Accounts payable — are the obligations of an organization to other legal entities or individuals that arise in cases when the company has acquired goods or services on deferred payment terms, has not paid taxes and fees, has wage arrears to employees, or has received loans and other liabilities. Accounts payable arise when an organization has already received some benefit but has not yet paid for it.Main types of accounts payable
| Type of liability | Example |
|---|---|
| To suppliers and contractors | Goods received but not yet paid for |
| Taxes and fees | VAT, income tax, etc., not paid on time |
| Salaries | Employee wages not paid |
| To budgets | Insurance contributions to funds not paid |
| To founders | Founders provided borrowed funds |
| To banks | Overdue loan payments |
| Other | Fines, penalties, forfeits, customer prepayments, etc. |
Impact on the company's financial performance
- Liquidity and solvency
Accounts payable are part of short-term liabilities, so they affect liquidity ratios - Financial stability
The higher the share of borrowed funds (including accounts payable), the lower the company's level of independence - Capital turnover
Moderate accounts payable can positively affect working capital by allowing the company to use “free” financing from suppliers (payment deferrals) - Risks and reputation
Large and especially overdue accounts payable may indicate financial difficulties. This can deter investors, partners, and lenders, and at a critical level of debt and lack of resources to repay it, bankruptcy proceedings may be initiated
Annual Accounts Payables Athira Pharma
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 319 K | 129 K | 2.5 M | 567 K | 1.16 M | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 2.5 M | 129 K | 935 K |
Quarterly Accounts Payables Athira Pharma
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 266 K | 171 K | 867 K | 319 K | 388 K | 475 K | 681 K | 129 K | 1.71 M | 612 K | 892 K | 2.5 M | 751 K | 605 K | 1.43 M | 567 K | 959 K | 1.17 M | 1.69 M | 1.16 M | 1.16 M | 1.16 M | 1.16 M | 421 K | 421 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 2.5 M | 129 K | 866 K |
Accounts Payables of other stocks in the Biotechnology industry
| Issuer | Accounts Payables | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Acer Therapeutics
ACER
|
3.81 M | - | 2.71 % | $ 14 M | ||
|
Adaptimmune Therapeutics plc
ADAP
|
8.13 M | - | -15.15 % | $ 60.3 M | ||
|
Adverum Biotechnologies
ADVM
|
1.61 M | - | - | $ 86.2 M | ||
|
ANI Pharmaceuticals
ANIP
|
45.7 M | $ 80.34 | - | $ 1.55 B | ||
|
Acasti Pharma
ACST
|
601 K | - | 4.01 % | $ 150 M | ||
|
Aptorum Group Limited
APM
|
3.24 M | $ 0.84 | 1.96 % | $ 4.58 M | ||
|
I-Mab
IMAB
|
570 M | - | - | $ 866 M | ||
|
Applied Genetic Technologies Corporation
AGTC
|
2.91 M | - | - | $ 26.5 M | ||
|
Adagene
ADAG
|
4.24 M | $ 2.67 | - | $ 150 M | ||
|
AlloVir
ALVR
|
247 K | - | 4.14 % | $ 49.1 M | ||
|
Ampio Pharmaceuticals
AMPE
|
750 K | - | -11.43 % | $ 502 K | ||
|
Applied Molecular Transport
AMTI
|
1.58 M | - | - | $ 10.1 M | ||
|
ARCA biopharma
ABIO
|
3.46 M | - | 1052.0 % | $ 415 M | ||
|
Acorda Therapeutics
ACOR
|
13.4 M | - | -24.86 % | $ 820 K | ||
|
Akero Therapeutics
AKRO
|
9.03 M | - | - | $ 3.67 B | ||
|
Aeglea BioTherapeutics
AGLE
|
677 K | - | - | $ 1.01 B | ||
|
Akebia Therapeutics
AKBA
|
14.6 M | $ 1.5 | - | $ 281 M | ||
|
Aptose Biosciences
APTO
|
1.26 M | - | -45.71 % | $ 1.2 M | ||
|
Albireo Pharma
ALBO
|
6.52 M | - | -0.23 % | $ 916 M | ||
|
Allena Pharmaceuticals
ALNA
|
1.03 M | - | 3.16 % | $ 1.9 M | ||
|
Aptinyx
APTX
|
724 K | - | -39.0 % | $ 4.57 M | ||
|
Aravive
ARAV
|
8.76 M | - | -13.39 % | $ 1.45 M | ||
|
Cabaletta Bio
CABA
|
4.55 M | $ 2.44 | - | $ 2.85 M | ||
|
Arena Pharmaceuticals
ARNA
|
13.3 M | - | -6.81 % | $ 3.04 B | ||
|
Aridis Pharmaceuticals
ARDS
|
2.31 M | - | 17.91 % | $ 11.1 M | ||
|
AgeX Therapeutics
AGE
|
1.41 M | - | -10.17 % | $ 12.2 K | ||
|
Athersys
ATHX
|
9.16 M | - | 3.77 % | $ 22.4 M | ||
|
Akouos
AKUS
|
1.28 M | - | 0.23 % | $ 488 M | ||
|
Avenue Therapeutics
ATXI
|
155 K | - | -52.27 % | $ 4.45 M | ||
|
Can-Fite BioPharma Ltd.
CANF
|
561 K | $ 4.22 | - | $ 9.18 B | ||
|
Autolus Therapeutics plc
AUTL
|
1.97 M | $ 1.46 | - | $ 373 M | ||
|
Compugen Ltd.
CGEN
|
1.84 M | $ 1.71 | - | $ 153 M | ||
|
Amneal Pharmaceuticals
AMRX
|
153 M | $ 14.52 | - | $ 4.49 B | ||
|
AVROBIO
AVRO
|
27 K | - | 1083.1 % | $ 745 M | ||
|
Alpine Immune Sciences
ALPN
|
4.29 M | - | - | $ 2.17 B | ||
|
Ayala Pharmaceuticals
AYLA
|
4.08 M | - | - | $ 7.46 M |